124 related articles for article (PubMed ID: 11122094)
41. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
42. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
Bianco E; Marcucci F; Mele A; Musto P; Cotichini R; Sanpaolo MG; Iannitto E; De Renzo A; Martino B; Specchia G; Montanaro M; Barbui AM; Nieddu R; Pagano L; Rapicetta M; Franceschi S; Mandelli F; Pulsoni A;
Haematologica; 2004 Jan; 89(1):70-6. PubMed ID: 14754608
[TBL] [Abstract][Full Text] [Related]
43. Cleaved L-selectin concentrations in meningeal leukaemia.
Stucki A; Cordey AS; Monai N; de Flaugergues JC; Schapira M; Spertini O
Lancet; 1995 Feb; 345(8945):286-9. PubMed ID: 7530792
[TBL] [Abstract][Full Text] [Related]
44. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry.
Chant ID; Rose PE; Morris AG
Br J Haematol; 1995 May; 90(1):163-8. PubMed ID: 7786780
[TBL] [Abstract][Full Text] [Related]
45. Urokinase-type plasminogen activator is increased in the involuting ventral prostate of castrated rats.
Andreasen PA; Kristensen P; Lund LR; Danø K
Endocrinology; 1990 May; 126(5):2567-76. PubMed ID: 2109689
[TBL] [Abstract][Full Text] [Related]
46. A case-control study to investigate the risk of leukaemia associated with exposure to benzene in petroleum marketing and distribution workers in the United Kingdom.
Rushton L; Romaniuk H
Occup Environ Med; 1997 Mar; 54(3):152-66. PubMed ID: 9155776
[TBL] [Abstract][Full Text] [Related]
47. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
48. Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism.
Moir E; Booth NA; Bennett B; Robbie LA
Br J Haematol; 2001 Apr; 113(1):72-80. PubMed ID: 11328284
[TBL] [Abstract][Full Text] [Related]
49. Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11).
Neudenberger J; Hotfilder M; Rosemann A; Langebrake C; Reinhardt D; Pieters R; Schrauder A; Schrappe M; Röttgers S; Harbott J; Vormoor J
Br J Haematol; 2006 May; 133(3):337-44. PubMed ID: 16643437
[TBL] [Abstract][Full Text] [Related]
50. ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises.
Ponzetto C; Guerrasio A; Rosso C; Avanzi G; Tassinari A; Zaccaria A; LoCoco F; Foa R; Basso G; Abate ML
Br J Haematol; 1990 Sep; 76(1):39-44. PubMed ID: 2223647
[TBL] [Abstract][Full Text] [Related]
51. Platelet function in acute leukemias.
Naresh KN; Sivasankaran P; Veliath AJ
J Assoc Physicians India; 1993 Jun; 41(6):377-8. PubMed ID: 8005978
[TBL] [Abstract][Full Text] [Related]
52. Terminal deoxynucleotidyl transferase measurements in the differential diagnosis of adult leukaemias.
Hutton JJ; Coleman MS
Br J Haematol; 1976 Nov; 34(3):447-56. PubMed ID: 62584
[TBL] [Abstract][Full Text] [Related]
53. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Robbie LA; Dummer S; Booth NA; Adey GD; Bennett B
Br J Haematol; 2000 May; 109(2):342-8. PubMed ID: 10848822
[TBL] [Abstract][Full Text] [Related]
54. Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.
Lijnen HR; Van Hoef B; Collen D
Eur J Biochem; 1996 Nov; 241(3):840-8. PubMed ID: 8944773
[TBL] [Abstract][Full Text] [Related]
55. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.
Lijnen HR; Wagner EF; Collen D
Thromb Haemost; 1997 Feb; 77(2):362-7. PubMed ID: 9157597
[TBL] [Abstract][Full Text] [Related]
56. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
57. Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation.
Chapman HA; Stone OL; Vavrin Z
J Clin Invest; 1984 Mar; 73(3):806-15. PubMed ID: 6368589
[TBL] [Abstract][Full Text] [Related]
58. Differential expression of terminal transferase (TdT) in acute lymphocytic leukaemia expressing myeloid antigens and TdT positive acute myeloid leukaemia as compared to myeloid antigen negative acute lymphocytic leukaemia.
Paietta E; Racevskis J; Bennett JM; Wiernik PH
Br J Haematol; 1993 Jul; 84(3):416-22. PubMed ID: 8217792
[TBL] [Abstract][Full Text] [Related]
59. Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour.
Dong Q; Zhou MH; Subbarao V; Ts'ao CH
Br J Exp Pathol; 1988 Oct; 69(5):685-95. PubMed ID: 3143395
[TBL] [Abstract][Full Text] [Related]
60. Lymphokine-activated killer cytotoxicity against leukaemic blast cells.
Tratkiewicz JA; Szer J; Boyd RL
Clin Exp Immunol; 1990 Apr; 80(1):94-9. PubMed ID: 2323104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
